Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
83.95 EUR | -0.18% | -2.10% | -11.60% |
12:46pm | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
05-17 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
Sales 2024 * | 2.8B 3.04B 239B | Sales 2025 * | 2.77B 3B 236B | Capitalization | 20.55B 22.3B 1,755B |
---|---|---|---|---|---|
Net income 2024 * | -415M -451M -35.45B | Net income 2025 * | -491M -533M -41.94B | EV / Sales 2024 * | 2.06 x |
Net cash position 2024 * | 14.78B 16.04B 1,262B | Net cash position 2025 * | 13.76B 14.94B 1,176B | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
-49
x | P/E ratio 2025 * |
-43.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.48% |
Latest transcript on BioNTech SE
1 week | -2.10% | ||
Current month | +1.26% | ||
1 month | +2.56% | ||
3 months | -0.47% | ||
6 months | -6.82% | ||
Current year | -11.60% |
Managers | Title | Age | Since |
---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 01/06/08 |
Özlem Türeci
FOU | Founder | 57 | 01/06/08 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 30/06/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 69 | 31/12/21 |
Director/Board Member | 67 | 01/06/08 | |
Helmut Jeggle
CHM | Chairman | 53 | 01/06/08 |
Date | Price | Change |
---|---|---|
21/05/24 | 83.95 | -0.18% |
20/05/24 | 84.1 | +0.90% |
17/05/24 | 83.35 | -2.51% |
16/05/24 | 85.5 | +1.00% |
15/05/24 | 84.65 | -0.41% |
Real-time BOERSE MUENCHEN, May 21, 2024 at 05:05 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.38% | 115B | |
+13.04% | 107B | |
-3.99% | 21.6B | |
-5.62% | 18.23B | |
-39.93% | 17.62B | |
+7.51% | 14.26B | |
+33.73% | 12.37B | |
-28.32% | 8.28B | |
+18.47% | 8.26B |
- Stock Market
- Equities
- BNTX Stock
- 22UA Stock